Peripheral Arterial Disease | Treatment Algorithms | Claims Data Analysis | US | 2018

Treatment of peripheral arterial disease (PAD) has not changed significantly in recent years, and the typically prescribed drug classes for the prevention of atherothrombotic events are awash with generic options. Merck & Co. launched Zontivity for PAD in 2014, but performance has been much lower than initially expected; Aralez Pharmaceuticals now has US rights to this product. PAD Treatment Algorithms presents insights into the treatment practices of a disease that holds huge market opportunity for an agent that significantly outperforms current treatment approaches.

QUESTIONS ANSWERED:

What patient share do key therapies and brands garner by line of therapy in newly diagnosed PAD patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed PAD patients?
How have Zontivity and generic rosuvastatin been integrated into the treatment algorithm?
What proportion of PAD patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
What percentage of PAD patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
What are the product-level compliance and persistency rates among drug-treated patients with PAD?

Contact sales account_box

Report

Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)

Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…

north_east

Report

Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)

First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…

north_east

Report

Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)

Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…

north_east

Report

Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer

China’s breast cancer market continues to evolve rapidly, driven by rising incidence and expanding systemic treatment options. Several new and emerging therapies are expected to gain approval for…

north_east

Report

Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)

The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…

north_east

Product logins

Peripheral Arterial Disease | Treatment Algorithms | Claims Data Analysis | US | 2018

Related Market Assessment Reports

Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)

Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)

Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)

Breast Cancer – Geographic Focus: China – China In-Depth – Breast Cancer

Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)

Follow us

Contact us